189 related articles for article (PubMed ID: 28664409)
1. Surfen is a broad-spectrum calcium channel inhibitor with analgesic properties in mouse models of acute and chronic inflammatory pain.
Rivas-Ramirez P; Gadotti VM; Zamponi GW; Weiss N
Pflugers Arch; 2017 Oct; 469(10):1325-1334. PubMed ID: 28664409
[TBL] [Abstract][Full Text] [Related]
2. Analgesic effect of a broad-spectrum dihydropyridine inhibitor of voltage-gated calcium channels.
Gadotti VM; Bladen C; Zhang FX; Chen L; Gündüz MG; Şimşek R; Şafak C; Zamponi GW
Pflugers Arch; 2015 Dec; 467(12):2485-93. PubMed ID: 26286466
[TBL] [Abstract][Full Text] [Related]
3. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats.
Jarvis MF; Scott VE; McGaraughty S; Chu KL; Xu J; Niforatos W; Milicic I; Joshi S; Zhang Q; Xia Z
Biochem Pharmacol; 2014 Jun; 89(4):536-44. PubMed ID: 24726441
[TBL] [Abstract][Full Text] [Related]
4. Effect of ABT-639 on Cav3.2 channel activity and its analgesic actions in mouse models of inflammatory and neuropathic pain.
Antunes FTT; Huang S; Chen L; Zamponi GW
Eur J Pharmacol; 2024 Mar; 967():176416. PubMed ID: 38342359
[TBL] [Abstract][Full Text] [Related]
5. Characterization of novel cannabinoid based T-type calcium channel blockers with analgesic effects.
Bladen C; McDaniel SW; Gadotti VM; Petrov RR; Berger ND; Diaz P; Zamponi GW
ACS Chem Neurosci; 2015 Feb; 6(2):277-87. PubMed ID: 25314588
[TBL] [Abstract][Full Text] [Related]
6. Effect of the T-type channel blocker KYS-05090S in mouse models of acute and neuropathic pain.
M'Dahoma S; Gadotti VM; Zhang FX; Park B; Nam JH; Onnis V; Balboni G; Lee JY; Zamponi GW
Pflugers Arch; 2016 Feb; 468(2):193-9. PubMed ID: 26354962
[TBL] [Abstract][Full Text] [Related]
7. Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model.
Son WS; Jeong KS; Lim SM; Pae AN
Bioorg Med Chem Lett; 2019 May; 29(10):1168-1172. PubMed ID: 30928197
[TBL] [Abstract][Full Text] [Related]
8. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker.
Abbadie C; McManus OB; Sun SY; Bugianesi RM; Dai G; Haedo RJ; Herrington JB; Kaczorowski GJ; Smith MM; Swensen AM; Warren VA; Williams B; Arneric SP; Eduljee C; Snutch TP; Tringham EW; Jochnowitz N; Liang A; Euan MacIntyre D; McGowan E; Mistry S; White VV; Hoyt SB; London C; Lyons KA; Bunting PB; Volksdorf S; Duffy JL
J Pharmacol Exp Ther; 2010 Aug; 334(2):545-55. PubMed ID: 20439438
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and characterization of a disubstituted piperazine derivative with T-type channel blocking action and analgesic properties.
Pudukulatham Z; Zhang FX; Gadotti VM; M'Dahoma S; Swami P; Tamboli Y; Zamponi GW
Mol Pain; 2016; 12():. PubMed ID: 27053601
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain.
Teleb M; Zhang FX; Huang J; Gadotti VM; Farghaly AM; AboulWafa OM; Zamponi GW; Fahmy H
Bioorg Med Chem; 2017 Mar; 25(6):1926-1938. PubMed ID: 28233679
[TBL] [Abstract][Full Text] [Related]
11. Analgesic properties of S100A9 C-terminal domain: a mechanism dependent on calcium channel inhibition.
Dale CS; Altier C; Cenac N; Giorgi R; Juliano MA; Juliano L; Zamponi GW; Vergnolle N
Fundam Clin Pharmacol; 2009 Aug; 23(4):427-38. PubMed ID: 19515068
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic insights into the analgesic efficacy of A-1264087, a novel neuronal Ca(2+) channel blocker that reduces nociception in rat preclinical pain models.
Zhu CZ; Vortherms TA; Zhang M; Xu J; Swensen AM; Niforatos W; Neelands T; Milicic I; Lewis LG; Zhong C; Gauvin D; Mikusa J; Zhan C; Pai M; Roderwald V; Chu KL; Cole EE; Bespalov A; Searle XB; McGaraughty S; Bitner RS; Jarvis MF; Bannon AW; Joshi SK; Scott VE; Lee CH
J Pain; 2014 Apr; 15(4):387.e1-14. PubMed ID: 24374196
[TBL] [Abstract][Full Text] [Related]
13. Voltage gated sodium and calcium channel blockers for the treatment of chronic inflammatory pain.
Rahman W; Dickenson AH
Neurosci Lett; 2013 Dec; 557 Pt A():19-26. PubMed ID: 23941888
[TBL] [Abstract][Full Text] [Related]
14. Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain.
Shao PP; Ye F; Chakravarty PK; Varughese DJ; Herrington JB; Dai G; Bugianesi RM; Haedo RJ; Swensen AM; Warren VA; Smith MM; Garcia ML; McManus OB; Lyons KA; Li X; Green M; Jochnowitz N; McGowan E; Mistry S; Sun SY; Abbadie C; Kaczorowski GJ; Duffy JL
J Med Chem; 2012 Nov; 55(22):9847-55. PubMed ID: 23098566
[TBL] [Abstract][Full Text] [Related]
15. Icilin reduces voltage-gated calcium channel currents in naïve and injured DRG neurons in the rat spinal nerve ligation model.
Hagenacker T; Lampe M; Schäfers M
Brain Res; 2014 Apr; 1557():171-9. PubMed ID: 24560602
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological mechanisms of alcohol analgesic-like properties in mouse models of acute and chronic pain.
Neddenriep B; Bagdas D; Contreras KM; Ditre JW; Wolstenholme JT; Miles MF; Damaj MI
Neuropharmacology; 2019 Dec; 160():107793. PubMed ID: 31562845
[TBL] [Abstract][Full Text] [Related]
17. KST5468, a new T-type calcium channel antagonist, has an antinociceptive effect on inflammatory and neuropathic pain models.
Lee MJ; Shin TJ; Lee JE; Choo H; Koh HY; Chung HJ; Pae AN; Lee SC; Kim HJ
Pharmacol Biochem Behav; 2010 Dec; 97(2):198-204. PubMed ID: 20678515
[TBL] [Abstract][Full Text] [Related]
18. Antinociceptive effect of different types of calcium channel inhibitors and the distribution of various calcium channel alpha 1 subunits in the dorsal horn of spinal cord in mice.
Murakami M; Nakagawasai O; Suzuki T; Mobarakeh II; Sakurada Y; Murata A; Yamadera F; Miyoshi I; Yanai K; Tan-No K; Sasano H; Tadano T; Iijima T
Brain Res; 2004 Oct; 1024(1-2):122-9. PubMed ID: 15451373
[TBL] [Abstract][Full Text] [Related]
19. NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors.
Berger ND; Gadotti VM; Petrov RR; Chapman K; Diaz P; Zamponi GW
Mol Pain; 2014 Dec; 10():77. PubMed ID: 25481027
[TBL] [Abstract][Full Text] [Related]
20. Targeting Ca2+ channels to treat pain: T-type versus N-type.
Altier C; Zamponi GW
Trends Pharmacol Sci; 2004 Sep; 25(9):465-70. PubMed ID: 15559248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
